Search Within

Melanoma Disease Management Team

Formats
  1. Journal Article (1608)
  2. Meeting Abstract (791)
  3. Book Section (104)
  4. Review (72)
  5. Editorial (58)
  6. Research Letter (45)
  7. Guidelines (26)
  8. Correspondence (23)
  9. Conference Paper (22)
  10. Miscellaneous (16)
  11. Book Whole (11)
Groups
  1. Department of Medicine (1694)
  2. Survivorship Research (1196)
  3. Solid Tumor Oncology Division (1054)
  4. Department of Pathology and Laboratory Medicine (958)
  5. Surgery (948)
  6. Melanoma and Immunotherapeutics Service (793)

More Groups

People
  1. Klaus Busam (699)
  2. Daniel Coit (543)
  3. Allan Halpern (402)
  4. Michael Postow (369)
  5. Alexander Shoushtari (247)
  6. Jedd Wolchok (222)

More People

Years
  1. 2025 (95)
  2. 2024 (138)
  3. 2023 (160)
  4. 2022 (167)
  5. 2021 (149)
  6. 2020 (142)

More Years

Publications
  1. Journal of Clinical Oncology (269)
  2. Annals of Surgical Oncology (221)
  3. Journal of the American Academy of Dermatology (123)
  4. Journal of Investigative Dermatology (84)
  5. Modern Pathology (67)
  6. Journal for ImmunoTherapy of Cancer (65)

More Publications

Publishers
  1. Springer (343)
  2. American Society of Clinical Oncology (285)
  3. Elsevier Inc. (231)
  4. Lippincott Williams & Wilkins (229)
  5. Wiley Blackwell (163)
  6. Elsevier Science, Inc. (160)

More Publishers

Results (2776)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Impact of source position and traveling time on HDR skin surface applicator dosimetry
    Meeting Abstract

    Jeong, J.; Barker, C.; Zaider, M.; Cohen, G.
    Medical Physics (2015)

    Fulltext@MSK | Save
  • Safety of pembrolizumab (pem) in patients (pts) who stopped ipilimumab (ipi) due to immune-related adverse events
    Meeting Abstract

    Shoushtari, A. N.; Postow, M. A.; Horvat, T. Z.; Adel, N. G.; Dang, T.; Chapman, P. B.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma
    Meeting Abstract

    Ribas, A.; Butler, M.; Lutzky, J.; Lawrence, D. P.; Robert, C.; Miller, W.; Linette, G. P.; Ascierto, P. A.; Kuzel, T.; Algazi, A. P.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Investigation of intrapatient heterogeneity in the tumor infiltrating T cell repertoire in patients with metastatic melanoma treated with pembrolizumab
    Meeting Abstract

    Munhoz, R. R.; Merghoub, T.; Emerson, R. O.; Callahan, M. K.; Wolchok, J. D.; Postow, M. A.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Safety of infusing ipilimumab (ipi) over 30 minutes (min)
    Meeting Abstract

    Momtaz, P.; Park, V.; Panageas, K.; Guillen, J. D.; Postow, M. A.; Callahan, M. K.; Wolchok, J. D.; Chapman, P. B.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Clinical response, progression-free survival (PFS), and safety in patients (pts) with advanced melanoma (MEL) receiving nivolumab (NIVO) combined with ipilimumab (IPI) vs IPI monotherapy in CheckMate 069 study
    Meeting Abstract

    Hodi, F. S.; Postow, M. A.; Chesney, J. A.; Pavlick, A. C.; Robert, C.; Grossmann, K. F.; McDermott, D. F.; Linette, G. P.; Meyer, N.; Giguere, J. K.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Response to anti-PD1/PDL1 therapy in patients with metastatic desmoplastic melanoma
    Meeting Abstract

    Eroglu, Z.; Kim, D. W.; Johnson, D. B.; Algazi, A. P.; Munhoz, R. R.; Liniker, E.; Kong, B.; Khurana, N.; Chmielowski, B.; Sosman, J. A.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Metastatic non-uterine leiomyosarcoma: Prognostic factors, overall survival and chemotherapy outcomes
    Meeting Abstract

    D'Angelo, S. P.; Shoushtari, A. N.; Landa, J.; Kuk, D.; Sanchez, A. J.; Lala, B.; Dickson, M. A.; Gounder, M. M.; Keohan, M. L.; Tap, W. D.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • A phase Ib/II study of MEK162 (binimetinib [BINI]) in combination with imatinib in patients with advanced gastrointestinal stromal tumor (GIST)
    Meeting Abstract

    Chi, P.; Qin, L. X.; D'Angelo, S. P.; Dickson, M. A.; Gounder, M. M.; Keohan, M. L.; Shoushtari, A. N.; Condy, M. M.; Konen, T.; Fruauff, A.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Effect of nivolumab (NIVO) in combination with ipilimumab (IPI) versus IPI alone on quality of life (QoL) in patients (pts) with treatment-naïve advanced melanoma (MEL): Results of a phase II study (CheckMate 069)
    Meeting Abstract

    Abernethy, A. P.; Postow, M. A.; Chesney, J. A.; Grossmann, K. F.; Taylor, F.; Coon, C.; Gilloteau, I.; Dastani, H.; Gagnier, P.; Robert, C.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save